Skip to main content
Equibles
PACB logo

PACB · Pacific Biosciences Of California, Inc. · Webcasts, Transcripts & Audio

Track PACB — free

Use PACB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PACB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.54 +0.03 (+1.20%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$503.55M
Shares
310.83M
Volume · Oct 2 26.01M Avg daily vol (3M) 8.82M

Pacific Biosciences Of California, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Pacific Biosciences Of California, Inc. (PACB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼7.4% $32.31M −$76.97M '22 Q3 22-10-26 ▼24.1% $27.35M −$84.38M '22 Q4 23-01-09 ▲17.3% $38.90M −$88.02M '23 Q1 23-05-02 ▲34.1% $47.57M −$69.83M '23 Q2 23-08-02 ▲72.4% $55.69M −$66.87M '23 Q3 23-10-30 ▲113.3% $58.36M −$82.02M '23 Q4 24-02-15 ▼0.2% $38.81M −$78.18M '24 Q1 24-05-09 ▼24.3% $36.01M −$173.32M '24 Q2 24-08-07 ▼28.2% $39.97M −$60.73M '24 Q3 24-11-07 ▼32.8% $39.22M $2.37M '24 Q4 25-02-13 ▼4.3% $37.15M −$426.07M '25 Q1 25-04-09 ▲10.4% $39.77M −$41.93M '25 Q2 25-08-07 ▼3.8% $38.44M −$38.00M '25 Q3 25-11-05 ▲13.8% $44.65M −$40.37M '25 Q4 26-02-12 ▲0.1% $37.18M −$8.28M '26 Q1 26-05-07 LATEST ▼1.9% $39.01M −$44.74M '26 Q2 26-08-05
Annual General Meeting
Investor event
2026-12-01
Pacific Biosciences Of California, Inc. (PACB) December 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-11-18
Pacific Biosciences Of California, Inc. (PACB) November 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-11-17
Pacific Biosciences Of California, Inc. (PACB) November 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-09-24
Pacific Biosciences Of California, Inc. (PACB) September 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Pacific Biosciences Of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Balanced tone HiFi platform and consumables Sparknext chemistry launch Clinical market growth
Revenue
$39.01M
▼ 1.9% YoY
Diluted EPS
$-0.14
Gross margin
32.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Pacific Biosciences Of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Positive tone Consumables / Clinical Growth Vega Instruments Revio Installed Base
Revenue
$37.18M
▲ 0.1% YoY
Diluted EPS
$-0.03
Gross margin
34.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Pacific Biosciences Of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
Positive tone Instrument Placements (Revio and Vega) Consumables Growth and Clinical Adoption Gross Margin Expansion
Revenue
$44.65M*
▲ 13.8% YoY
Gross margin
37.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Pacific Biosciences Of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
Positive tone Revio System Clinical and HiFi Adoption Revenue and Guidance
Revenue
$38.44M
▼ 3.8% YoY
Diluted EPS
$-0.13
Gross margin
41.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Pacific Biosciences Of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
Positive tone Revenue and growth Revio placements and utilization Vega platform adoption
Revenue
$39.77M
▲ 10.4% YoY
Diluted EPS
$-0.14
Gross margin
36.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-09
Pacific Biosciences Of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
Cautious tone Product platforms: Revio, Vega, Spark, multi-use SMRT Cells Clinical and regional growth opportunities (EMEA, hospitals) Consumables growth and pull-through
Revenue
$37.15M
▼ 4.3% YoY
Diluted EPS
$-1.44
Gross margin
-3.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Pacific Biosciences Of California, Inc. (PACB) Q4 2024 Earnings Call Transcript
Balanced tone Macroeconomic and NIH Funding Uncertainty Revio and Consumables Vega Benchtop Platform
Revenue
$39.22M*
▼ 32.8% YoY
Gross margin
25.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Pacific Biosciences Of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
Positive tone Product Launches (SPRQ/SpaRC, Vega) Revio Platform Adoption SoftBank Note Exchange / Balance Sheet
Revenue
$39.97M
▼ 28.2% YoY
Diluted EPS
$-0.22
Gross margin
25.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Pacific Biosciences Of California, Inc. (PACB) Q2 2024 Earnings Call Transcript
Cautious tone Revio Instrument Demand Challenges Consumables and Revio Utilization Restructuring and Cost Reduction
Revenue
$36.01M
▼ 24.3% YoY
Diluted EPS
$-0.64
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Pacific Biosciences Of California, Inc. (PACB) Q1 2024 Earnings Call Transcript
Cautious tone Revio instrument sales cycle elongation Cost reduction and margin improvement Long-term cash flow positive goal by 2026
Revenue
$38.81M
▼ 0.2% YoY
Diluted EPS
$-0.29
Gross margin
29.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Pacific Biosciences Of California, Inc. (PACB) Q4 2023 Earnings Call Transcript
Positive tone Revio instrument adoption and installed base Onso short-read platform ramp Consumables pull-through and Revio utilization
Revenue
$58.36M*
▲ 113.3% YoY
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
Pacific Biosciences Of California, Inc. (PACB) Q3 2023 Earnings Call Transcript
Revenue
$55.69M
▲ 72.4% YoY
Diluted EPS
$-0.26
Gross margin
32.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pacific Biosciences Of California, Inc. (PACB) Q2 2023 Earnings Call Transcript
Revenue
$47.57M
▲ 34.1% YoY
Diluted EPS
$-0.28
Gross margin
32.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Pacific Biosciences Of California, Inc. (PACB) Q1 2023 Earnings Call Transcript
Revenue
$38.90M
▲ 17.3% YoY
Diluted EPS
$-0.36
Gross margin
25.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Pacific Biosciences Of California, Inc. (PACB) Q4 2022 Earnings Call Transcript
Revenue
$27.35M*
▼ 24.1% YoY
Gross margin
18.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Pacific Biosciences Of California, Inc. (PACB) Q3 2022 Earnings Call Transcript
Revenue
$32.31M
▼ 7.4% YoY
Diluted EPS
$-0.34
▼ 525% YoY
Gross margin
41.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2022 Earnings Call Transcript
Revenue
$35.47M
▲ 15.9% YoY
Diluted EPS
$-0.32
Gross margin
45.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Pacific Biosciences Of California, Inc. (PACB) Q1 2022 Earnings Call Transcript
Revenue
$33.17M
▲ 14.4% YoY
Diluted EPS
$-0.37
Gross margin
42.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Pacific Biosciences Of California, Inc. (PACB) Q4 2021 Earnings Call Transcript
Revenue
$36.02M*
▲ 43.3% YoY
Gross margin
46.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Pacific Biosciences Of California, Inc. (PACB) Q3 2021 Earnings Call Transcript
Revenue
$34.89M
▲ 82.8% YoY
Diluted EPS
$0.08
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2021 Earnings Call Transcript
Revenue
$30.61M
▲ 60.4% YoY
Diluted EPS
$-0.21
Gross margin
44.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Pacific Biosciences Of California, Inc. (PACB) Q1 2021 Earnings Call Transcript
Revenue
$29.00M
▲ 85.9% YoY
Diluted EPS
$-0.45
▼ 4600% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Pacific Biosciences Of California, Inc. (PACB) Q4 2020 Earnings Call Transcript
Revenue
$25.13M*
▼ 10% YoY
Gross margin
45.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Pacific Biosciences Of California, Inc. (PACB) Q3 2020 Earnings Call Transcript
Revenue
$19.08M
▼ 12.9% YoY
Diluted EPS
$-0.14
Gross margin
37.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Pacific Biosciences Of California, Inc. (PACB) Q2 2020 Earnings Call Transcript
Revenue
$19.08M
▼ 22.5% YoY
Diluted EPS
$-0.15
Gross margin
34.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Pacific Biosciences Of California, Inc. (PACB) Q1 2020 Earnings Call Transcript
Revenue
$15.60M
▼ 5% YoY
Diluted EPS
$0.01
Gross margin
48.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Pacific Biosciences Of California, Inc. (PACB) Q4 2019 Earnings Call
Revenue
$27.93M
▲ 43% YoY
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–31 of 31 webcasts
Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 4 filings 4 filers Visit website Investor relations